Breakfast Technical Briefing on Biotech Stocks -- Amicus Therapeutics, Argos Therapeutics, Array BioPharma, and Aurinia Pharma

Tuesday, September 26, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, September 26, 2017 /PRNewswire/ --

If you want a Stock Review on FOLD, ARGS, ARRY, or AUPH then come over

to and sign up for your free customized report. Today, shifts focus on Biotechnology, which presents opportunities to address some of the world's biggest challenges, including increasing
and ageing population, health care needs, resource efficiency, food security, climate change, and energy shortages. Lined up for assessment this morning are: Amicus Therapeutics Inc. (NASDAQ: FOLD), Argos Therapeutics Inc. (NASDAQ: ARGS), Array BioPharma Inc. (NASDAQ: ARRY), and Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH). Daily Stock Tracker published free research reports on these stocks today at:

Amicus Therapeutics 

Cranbury, New Jersey headquartered Amicus Therapeutics Inc.'s shares gained 0.14%, closing Monday's trading session at $14.63. The stock recorded a trading volume of 3.09 million shares. The Company's shares have advanced 11.42% in the last month, 45.72% over the previous three months, and 194.37% since the start of this year. The stock is trading 9.27% above its 50-day moving average and 67.46% above its 200-day moving average. Additionally, shares of Amicus Therapeutics, which engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases, have a Relative Strength Index (RSI) of 57.31.  

On September 13th, 2017, research firm Chardan Capital Markets reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $17.50 a share to $16.50 a share.

On September 20th, 2017, Amicus Therapeutics announced that John F. Crowley, Chairman and CEO, will participate in a corporate overview and fireside chat at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology on September 27th, 2017, at 1:00 p.m. ET in New York. A live webcast of the presentation will be available under the Investors section of the Company's corporate website. See our free and comprehensive research report on FOLD at:

Argos Therapeutics 

On Monday, shares in Durham, North Carolina headquartered Argos Therapeutics Inc. recorded a trading volume of 2.02 million shares. The stock dropped 4.33%, ending the day at $0.17. The Company's shares are trading below their 50-day moving average by 24.93%. Furthermore, shares of Argos Therapeutics, which focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases, have an RSI of 37.83.  

On September 06th, 2017, Argos Therapeutics reported that for the first time, a patient in the ongoing Phase-2 HIV eradication trial at the University of North Carolina has been dosed with AGS-004 dendritic cell therapy, which was manufactured utilizing RNA antigens from the patient's latent viral reservoir. To the Company's knowledge, this is also the first time that an HIV patient has received a therapy utilizing RNA antigens from his/her latent viral reservoir in a clinical trial conducted in the US. ARGS free research report is just a click away at:

Array BioPharma 

Boulder, Colorado headquartered Array BioPharma Inc.'s stock finished the day flat at $11.32 with a total trading volume of 2.85 million shares. The Company's shares have advanced 13.31% in the last one month, 25.50% in the previous three months, and 28.78% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 23.54% and 22.48%, respectively. Additionally, shares of Array BioPharma have an RSI of 66.36.  

On September 11th, 2017, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $13 a share to $15 a share.

On September 19th, 2017, Array BioPharma announced the closing of its underwritten public offering of 24,069,766 shares of its common stock, which includes 3,139,534 shares of common stock issued upon the exercise in full of the option to purchase additional shares granted to the underwriters, at a public offering price of $10.75 per share. The total gross proceeds from the offering are $258.75 million, before underwriting discounts and commissions and offering expenses. Sign up for your complimentary report on ARRY at:

Aurinia Pharmaceuticals 

Shares in Victoria, Canada headquartered Aurinia Pharmaceuticals Inc. ended yesterday's session 0.64% lower at $6.18. The stock recorded a trading volume of 633,279 shares. The Company's shares have advanced 1.81% in the last one month and 194.29% since the start of this year. The stock is trading 10.33% above its 200-day moving average. Moreover, shares of Aurinia Pharma have an RSI of 45.70.  

On September 19th, 2017, Aurinia Pharma announced that it will host an R&D Day on October 20th, 2017 at 8:00 a.m. ET in New York. Members of the Company's leadership team and external opinion leaders will provide R&D and commercial insights for voclosporin in lupus nephritis and new additional indications. A live webcast of the event, including slides, will be available under the Investors section of the Company's website. Register for free on and download the latest research report on AUPH at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store